NICE refuses to approve Lucentis for Diabetic Macular Oedema. 26/07/11

Available for over a year

We look at the impact of NICE's decision not to approve a drug used for treating diabetic macular oedema, a condition affecting 50 000 people in the UK. Plus more from Sight Vilage, the exhibition which showcases the latest technology for blind and partially sighted people.